Overexpressed cyclo-oxygenase-2 in the background liver is associated with the clinical course of hepatitis C virus-related cirrhosis patients after curative surgery for hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 8, 2007, Pages 1249-1255

  Morinaga, Soichiro ^a,c,d   Tarao, Kazuo ^a   Yamamoto, Yuji ^c   Nakamura, Yoshiyasu ^a   Rino, Yasushi ^b   Miyakawa, Kaoru ^a   Ohkawa, Shinichi ^a   Akaike, Makoto ^a   Sugimasa, Yukio ^a   Takemiya, Shoji ^a  

^a Kanagawa Cancer Center   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c Kanagawa Prefectural Ashigarakami Hospital   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

Author keywords

Cyclo oxygenase 2; Hepatitis C virus; Hepatocellular carcinoma; Liver cirrhosis

Indexed keywords

ALANINE AMINOTRANSFERASE; CYCLOOXYGENASE 2;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; FOLLOW UP; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 34547666468     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04367.x     Document Type: Article

References (26)

1. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammmtion, cancer, and development. Oncogene 1999 18 : 7908 16.
2. Kondo M, Yamamoto H, Nagano H et al. Increased expression of COX-2 in nontumor liver tissue is associated with shorter diseased-free survival in patients with hepatocellular carcinoma. Clin. Cancer Res. 1999 5 : 4005 12.
3. Koga H, Sakisaka S, Ohishi M et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999 29 : 688 96.
4. Morinaga S, Yamamoto Y, Noguchi Y et al. Cyclooxyganase-2 m RNA is up-regulated in cirrhotic or chronic hepatitis liver adjacent to hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2002 17 : 1110 15.
5. Mohammed NA, El-Aleem SA, El-Hafiz McMahon RFT. Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis. J. Clin. Pathol. 2004 57 : 350 4.
6. Sung YK, Hwang SY, Kim JO et al. The correlation between cyclooxygenase-2 expression and hepatocellular carcinogenesis. Mol. Cells 2004 17 : 35 8.
7. Cheng J, Imanishi H, Iijima H et al. Expression of cyclooxygenase 2 and cytosolic phospholipase A2 in the liver tissue of patients with chronic hepatitis and liver cirrhosis. Hepatol. Res. 2002 23 : 185 95.
8. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J. Hepatol. 1999 31 : 9 16.
9. Colombo M. Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma. J. Hepatol. 1999 31 : 25 30.
10. Ballardini G, Groff P, Zoli M et al. Increased risk of hepatocellular carcinoma development in patients with cirrhosis and with high hepatocellular proliferation. J. Hepatol. 1994 20 : 218 22.
11. Tarao K, Ohkawa S, Shimizu A et al. Significance of hepatocellular proliferation in the development of hepatocellular carcinoma from anti-hepatitis C virus-positive cirrhotic patients. Cancer 1994 73 : 1149 54.
12. Tarao K, Rino Y, Ohkawa S et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus associated cirrhosis. Cancer 1999 86 : 589 95.
13. Tarao K, Takemiya S, Tamai S et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer 1997 79 : 688 94.
14. Desmet UJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994 19 : 1513 20.
15. Sobin LH, Wittekind C. TNM Classification on Malignant Tumors, 6th edn. New York : Wiley-Liss, 2002.
16. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998 28 : 751 5.
17. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J. Gastroenterol. 2003 38 : 207 15.
18. Nanji AA, Miao L, Thomas P et al. Enhanced cyclooxygenase-2 gene expression in alcoholic liver disease in the rat. Gastroenterology 1997 112 : 943 51.
19. Denda A, Endoh T, Tang Q, Tsujiuchi T, Nakae D, Konishi Y. Prevention by inhibitors of arachidonic acid cascade of liver carcinogenesis, cirrhosis and oxidative DNA damage caused by a choline-deficient, 1-amino acid-defined diet in rats. Mutat. Res. 1998 402 : 279 88.
20. Coon JT, Ernst E. Complementary and alternative therapies in the treatment of chronic hepatitis C: a systemic review. J. Hepatol. 2004 40 : 491 500.
21. Lirussi F, Beccarello A, Bortolato L et al. Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease. Liver 1999 19 : 381 8.
22. Tsubota A, Kumada H, Arase Y et al. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients. Eur. J. Gastroenterol. Hepatol. 1999 11 : 1077 83.
23. Oka H, Yamamoto S, Kuroki T et al. Prospective study of chemoprevention of hepatocellular carcinoma with sho-saiko-to (TJ-1). Cancer 1995 76 : 743 9.
24. Arase Y, Ikeda K, Murashima N et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997 79 : 1494 500.
25. Kinzler KW, Vogelstein B. Landscaping the cancer terrain. Science 1998 280 : 1036 7.
26. Gasparini G, Longo R, Sarmiento R et al. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol. 2003 4 : 605 15.